272 related articles for article (PubMed ID: 28947033)
21. Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.
Chida-Nagai A; Sagawa K; Tsujioka T; Fujimoto T; Taniguchi K; Sasaki O; Izumi G; Yamazawa H; Masaki N; Manabe A; Takeda A
Heart Vessels; 2020 Sep; 35(9):1307-1315. PubMed ID: 32285188
[TBL] [Abstract][Full Text] [Related]
22. [Other causes of pulmonary arterial hypertension: pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, porto-pulmonary hypertension, HIV- associated pulmonary arterial hypertension].
Karakurt Z
Anadolu Kardiyol Derg; 2010 Aug; 10 Suppl 1():63-8. PubMed ID: 20819769
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary capillary hemangiomatosis in Chinese patients without EIF2AK4 mutations.
Li Y; Gu Y; Hong C; Deng Y; Chen Z; Jiang J
Pathol Res Pract; 2020 Sep; 216(9):153100. PubMed ID: 32825965
[TBL] [Abstract][Full Text] [Related]
24. Imatinib is partially effective for the treatment of pulmonary capillary hemangiomatosis.
Adachi S; Hirashiki A; Kondo T; Nakaguro M; Ogawa A; Miyaji K; Matsubara H; Yokoi T; Murohara T
Intern Med; 2014; 53(6):603-7. PubMed ID: 24633031
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of oral pulmonary vasodilators in pulmonary veno-occlusive disease.
Nakamura J; Tsujino I; Shima H; Nakaya T; Sugimoto A; Sato T; Watanabe T; Ohira H; Suzuki M; Tsuneta S; Hisada R; Kato M; Konno S
Pulm Circ; 2022 Oct; 12(4):e12168. PubMed ID: 36523326
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive three-dimensional morphology of neoangiogenesis in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
Neubert L; Borchert P; Shin HO; Linz F; Wagner WL; Warnecke G; Laenger F; Haverich A; Stark H; Hoeper MM; Kuehnel M; Ackermann M; Jonigk D
J Pathol Clin Res; 2019 Apr; 5(2):108-114. PubMed ID: 30697960
[TBL] [Abstract][Full Text] [Related]
27. [Clinical characteristics and survival of patients with pulmonary veno-occlusive disease].
Jiang X; Chen FD; He J; Jiang R; Di RM; Zhao QH; Jing ZC
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):896-900. PubMed ID: 22321271
[TBL] [Abstract][Full Text] [Related]
28. Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease.
Okumura H; Nagaya N; Kyotani S; Sakamaki F; Nakanishi N; Fukuhara S; Yutani C
Chest; 2002 Sep; 122(3):1096-8. PubMed ID: 12226062
[TBL] [Abstract][Full Text] [Related]
29. [Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis].
Montani D; Dorfmuller P; Maitre S; Jaïs X; Sitbon O; Simonneau G; Humbert M
Presse Med; 2010 Jan; 39(1):134-43. PubMed ID: 19914027
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.
Frost AE; Barst RJ; Hoeper MM; Chang HJ; Frantz RP; Fukumoto Y; Galié N; Hassoun PM; Klose H; Matsubara H; Morrell NW; Peacock AJ; Pfeifer M; Simonneau G; Tapson VF; Torres F; Dario Vizza C; Lawrence D; Yang W; Felser JM; Quinn DA; Ghofrani HA
J Heart Lung Transplant; 2015 Nov; 34(11):1366-75. PubMed ID: 26210752
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature.
Almagro P; Julià J; Sanjaume M; González G; Casalots J; Heredia JL; Martínez J; Garau J
Medicine (Baltimore); 2002 Nov; 81(6):417-24. PubMed ID: 12441898
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary veno-occlusive disease: a case series and new observations.
Holcomb BW; Loyd JE; Ely EW; Johnson J; Robbins IM
Chest; 2000 Dec; 118(6):1671-9. PubMed ID: 11115457
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
Hoeper MM; Barst RJ; Bourge RC; Feldman J; Frost AE; Galié N; Gómez-Sánchez MA; Grimminger F; Grünig E; Hassoun PM; Morrell NW; Peacock AJ; Satoh T; Simonneau G; Tapson VF; Torres F; Lawrence D; Quinn DA; Ghofrani HA
Circulation; 2013 Mar; 127(10):1128-38. PubMed ID: 23403476
[TBL] [Abstract][Full Text] [Related]
34. Small Sample Lung Biopsy Findings in Patients With Clinicoradiologic Suspicion of Pulmonary Venoocclusive Disease-Pulmonary Capillary Hemangiomatosis.
Bal SK; Thangakunam B; Irodi A; Gupta M; Christopher DJ
J Bronchology Interv Pulmonol; 2016 Oct; 23(4):308-315. PubMed ID: 27623416
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary veno-occlusive disease.
Montani D; Lau EM; Dorfmüller P; Girerd B; Jaïs X; Savale L; Perros F; Nossent E; Garcia G; Parent F; Fadel E; Soubrier F; Sitbon O; Simonneau G; Humbert M
Eur Respir J; 2016 May; 47(5):1518-34. PubMed ID: 27009171
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.
Hatano M; Yao A; Shiga T; Kinugawa K; Hirata Y; Nagai R
Int Heart J; 2010 Jul; 51(4):272-6. PubMed ID: 20716845
[TBL] [Abstract][Full Text] [Related]
37. [Pulmonary capillary hemangiomatosis: a case report and literature review].
Xiong Y; Li XX; Mu XD; Li D; Wang Y; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Oct; 47(5):865-9. PubMed ID: 26474632
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary capillary haemangiomatosis: a distinct entity?
Weatherald J; Dorfmüller P; Perros F; Ghigna MR; Girerd B; Humbert M; Montani D
Eur Respir Rev; 2020 Jun; 29(156):. PubMed ID: 32461209
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib is effective in the treatment of pulmonary veno-occlusive disease.
Kataoka M; Yanagisawa R; Fukuda K; Yoshino H; Satoh T
Cardiology; 2012; 123(3):172-4. PubMed ID: 23128832
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary veno-occlusive disease: pathogenesis, risk factors, clinical features and diagnostic algorithm - state of the art.
Szturmowicz M; Kacprzak A; Szołkowska M; Burakowska B; Szczepulska E; Kuś J
Adv Respir Med; 2018; 86(3):. PubMed ID: 29960280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
